Table 5 Incremental cost-effectiveness ratios, societal perspective, 0 to 6 months
Incremental cost | Incremental effect | ICER | |||||
|---|---|---|---|---|---|---|---|
Mean; (95% bootstrap CI) | Mean; (95% bootstrap CI) | ||||||
CBT versus TAU | |||||||
Completers ( N =152) | |||||||
QALY (EQ-5D) | -2,061.9 | -3,168.9 | -954.9 | 0.01 | -0.00 | 0.03 | CBT dominant |
EQ VAS | -2,073.2 | -3,179.8 | -966.6 | 6.19 | 3.63 | 8.75 | CBT dominant |
ITT ( N =168) | |||||||
QALY (EQ-5D) | -2,158.8 | -3,357.1 | -960.5 | 0.02 | -0.00 | 0.03 | CBT dominant |
EQ VAS | -2,163.9 | -3,363.8 | -964.0 | 6.33 | 3.62 | 9.07 | CBT dominant |
PPA ( N =154) | |||||||
QALY (EQ-5D) | -2,368.9 | -3,599.1 | -1,138.6 | 0.02 | -0.00 | 0.03 | CBT dominant |
EQ VAS | -2,372.4 | -3,604.8 | -1,140.0 | 6.58 | 3.83 | 9.33 | CBT dominant |
CBT versus RPT | |||||||
Completers ( N =152) | |||||||
QALY (EQ-5D) | -2,386.9 | -3,485.4 | -1,288.3 | 0.01 | -0.00 | 0.03 | CBT dominant |
EQ VAS | -2,393.9 | -3,495.2 | -1,292.6 | 3.52 | 1.13 | 5.90 | CBT dominant |
ITT ( N =168) | |||||||
QALY (EQ-5D) | -2,304.7 | -3,326.6 | -1,282.7 | 0.01 | -0.00 | 0.03 | CBT dominant |
EQ VAS | -2,307.8 | -3,331.4 | -1,284.2 | 3.61 | 1.08 | 6.15 | CBT dominant |
PPA ( N =154) | |||||||
QALY (EQ-5D) | -2,550.3 | -3,624.9 | -1,475.7 | 0.01 | -0.00 | 0.03 | CBT dominant |
EQ VAS | -2,552.7 | -3,631.5 | -1,473.9 | 3.93 | 1.35 | 6.51 | CBT dominant |
RPT versus TAU | |||||||
Completers ( N =152) | |||||||
QALY (EQ-5D) | 324.9 | -894.8 | 1,544.7 | -0.00 | -0.02 | 0.01 | TAU dominant |
EQ VAS | 320.7 | -894.3 | 1,535.6 | 2.67 | 0.56 | 4.79 | 120 |
ITT ( N =168) | |||||||
QALY (EQ-5D) | 145.9 | -1,150.7 | 1,442.5 | 0.00 | -0.01 | 0.02 | 79,071 |
EQ VAS | 143.9 | -1,150.8 | 1,438.6 | 2.72 | 0.42 | 5.02 | 53 |
PPA ( N =154) | |||||||
QALY (EQ-5D) | 181.4 | -1,127.9 | 1,490.7 | 0.00 | -0.01 | 0.02 | 137,161 |
EQ VAS | 180.3 | -1,127.3 | 1,487.9 | 2.65 | 0.36 | 4.94 | 68 |